News

FDA halts Rocket Pharma's gene therapy trial as patient dies
The U.S. FDA has paused Rocket Pharmaceuticals' mid-stage gene therapy trial after a patient died from serious complications, ...
Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies
Rocket Pharmaceuticals shares plummeted 60% Tuesday after the firm said it halted a study of a gene-therapy drug for Danon ...
FDA halts Rocket Pharma's gene therapy trial as complications lead to patient death
The U.S. FDA has paused a mid-stage gene therapy trial by Rocket Pharmaceuticals after a patient suffered serious ...
CoreWeave, Rocket Pharmaceuticals, SoundHound: Trending Tickers
Barclays analysts downgraded CoreWeave (CRWV) to Equal Weight, raising valuation concerns. This is CoreWeave's first ...
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy ...
Rocket Pharma plunges after FDA clinical hold on mid-stage trial
Rocket Pharmaceuticals (RCKT) stock faces a 62% stock drop after FDA's hold on the company's Phase 2 gene therapy trial for ...
Fintel on MSN4d
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT)
Fintel reports that on May 28, 2025, Leerink Partners downgraded their outlook for Rocket Pharmaceuticals (NasdaqGM:RCKT) ...
Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold
Rocket Pharmaceuticals halted its Danon disease gene therapy trial after a patient death, with the FDA placing the study on ...
These Analysts Slash Their Forecasts On Rocket Pharmaceuticals
Jefferies analyst Andrew Tsai downgraded Rocket Pharmaceuticals from Buy to Hold and lowered the price target from $29 to ...
Rocket Pharmaceuticals: Despite FDA Clinical Hold On RP-A501, Prospects Remain Intact
FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow
Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt ...
Clinical Trials Arena on MSN6d
Patient dies in Rocket’s Phase II Danon disease gene therapy trial
The FDA ordered a clinical hold on Rocket Pharmaceuticals' Danon disease trial after the adverse event was first disclosed.